Kyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis at the American Academy of Dermatology Annual Meeting 2023
BEDMINSTER, N.J. and TOKYO, March 17, 2023 /PRNewswire/ — Kyowa Kirin Co., Ltd. (TSE: 4151) today announces that data from the Phase 2b study of rocatinlimab (KHK4083/AMG 451), an investigational product in patients with moderate-to-severe atopic dermatitis, will be presented in two…
Comments Off on Kyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis at the American Academy of Dermatology Annual Meeting 2023